LNP7457 / Lupin, Kaveri Therapeutics - LARVOL DELTA

A phase 1 dose escalation study of LNP7457 (PRMT5 inhibitor) in patients with advanced or metastatic solid tumors. (ASCO 2025) - "LNP7457 was well tolerated with desirable safety, PK/PD and preliminary efficacy profile. Clinical Trial Information: CTRI/2023/07/054753. Research Sponsor: Lupin Limited, India."

Clinical • Metastases • P1 data • Anemia • Breast Cancer • Cervical Cancer • Gallbladder Cancer • Head and Neck Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Solid Tumor • Thrombocytopenia • Uterine Cancer • PRMT5

Lupin Announces Presentation of Phase 1 Data on LNP7457 (PRMT5 inhibitor) at the American Society of Clinical Oncology - Annual Meeting 2025 (PRNewswire) - P1 | N=104 | "The presentation titled 'A phase 1 dose escalation study of LNP7457 (PRMT5 inhibitor) in patients with advanced or metastatic solid tumors,' will be featured in the Developmental Therapeutics-Molecularly Targeted Agents and Tumor Biology session....Key findings from the study include: LNP7457 is generally safe and well tolerated in patients with advanced or metastatic solid tumors, with desirable PK/PD profile and no impact of food on the pharmacokinetics. The maximum tolerated dose, recommended phase 2 dose was determined based on safety, efficacy, PK/PD data, aligning with preclinical findings and the known safety profile of PRMT5 inhibitors."

P1 data • Oncology • Solid Tumor